Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: A systematic review from sham CPAP randomized controlled trials

Sleep Medicine Reviews

Volumn 21, Issue , 2015, Pages 23-38

  Jullian Desayes, Ingrid ^a,b   Joyeux Faure, Marie ^a,b   Tamisier, Renaud ^a,b   Launois, Sandrine ^a,b   Borel, Anne Laure ^a,b   Levy, Patrick ^a,b   Pepin, Jean Louis ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cardiometabolic biomarkers; Continuous positive airway pressure; Obstructive sleep apnea; Randomized controlled trial

Indexed keywords

BIOLOGICAL MARKER; CATECHOLAMINE; CATECHOLAMINE DERIVATIVE; GLUCOSE; LIPID; LIVER ENZYME;

BLOOD CLOTTING; CARDIOMETABOLIC RISK; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHAM PROCEDURE; SLEEP DISORDERED BREATHING; SYMPATHETIC TONE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULITIS; METABOLISM; SLEEP APNEA, OBSTRUCTIVE;

BIOMARKERS; CATECHOLAMINES; CONTINUOUS POSITIVE AIRWAY PRESSURE; GLUCOSE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP APNEA, OBSTRUCTIVE;

EID: 84928065527     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2014.07.004     Document Type: Review

References (100)

1. Kohler M., Stradling J.R. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010, 7:677-685.
2. Lavie L., Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 2009, 33:1467-1484.
3. Levy P., Tamisier R., Minville C., Launois S., Pepin J.L. Sleep apnoea syndrome in 2011: current concepts and future directions. Eur Respir Rev 2011, 20:134-146.
4. McNicholas W.T., Bonsigore M.R. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007, 29:156-178.
5. Aron-Wisnewsky J., Minville C., Tordjman J., Levy P., Bouillot J.L., Basdevant A., et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. JHepatol 2012, 56:225-233.
6. Levy P., Bonsignore M.R., Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009, 34:243-260.
7. Drager L.F., Togeiro S.M., Polotsky V.Y., Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. JAm Coll Cardiol 2013, 62:569-576.
8. Pepin J.L., Tamisier R., Levy P. Obstructive sleep apnoea and metabolic syndrome: put CPAP efficacy in a more realistic perspective. Thorax 2012, 67:1025-1027.
9. Kohler M., Stoewhas A.C., Ayers L., Senn O., Bloch K.E., Russi E.W., et al. Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2011, 184:1192-1199.
10. Ayers L., Stoewhas A.C., Ferry B., Stradling J., Kohler M. Elevated levels of endothelial cell-derived microparticles following short-term withdrawal of continuous positive airway pressure in patients with obstructive sleep apnea: data from a randomized controlled trial. Respiration 2013, 85:478-485.
11. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003, 7:35-51.
12. Jelic S., Padeletti M., Kawut S.M., Higgins C., Canfield S.M., Onat D., et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008, 117:2270-2278.
13. Tamisier R., Pepin J.L., Remy J., Baguet J.P., Taylor J.A., Weiss J.W., et al. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J 2011, 37:119-128.
14. Dempsey J.A., Veasey S.C., Morgan B.J., O'Donnell C.P. Pathophysiology of sleep apnea. Physiol Rev 2010, 90:47-112.
15. Hedner J., Darpo B., Ejnell H., Carlson J., Caidahl K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995, 8:222-229.
16. Heitmann J., Ehlenz K., Penzel T., Becker H.F., Grote L., Voigt K.H., et al. Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients. Eur Respir J 2004, 23:255-262.
17. Pinto P., Barbara C., Montserrat J.M., Patarrao R.S., Guarino M.P., Carmo M.M., et al. Effects of CPAP on nitrate and norepinephrine levels in severe and mild-moderate sleep apnea. BMC Pulm Med 2013, 13:13.
18. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., Hernanz A., Hidalgo R., Martinez-Mateo V., et al. CPAP decreases plasma levels of soluble tumour necrosis factor-alpha receptor 1 in obstructive sleep apnoea. Eur Respir J 2008, 32:1009-1015.
19. Alonso-Fernandez A., Garcia-Rio F., Arias M.A., Hernanz A., de la Pena M., Pierola J., et al. Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax 2009, 64:581-586.
20. Ziegler M.G., Mills P.J., Loredo J.S., Ancoli-Israel S., Dimsdale J.E. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest 2001, 120:887-893.
21. Grote L., Kraiczi H., Hedner J. Reduced alpha- and beta(2)-adrenergic vascular response in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2000, 162:1480-1487.
22. Lam J.C., Lam B., Yao T.J., Lai A.Y., Ooi C.G., Tam S., et al. Arandomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J 2010, 35:138-145.
23. Phillips C.L., Yee B.J., Marshall N.S., Liu P.Y., Sullivan D.R., Grunstein R.R. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial. Am J Respir Crit Care Med 2011, 184:355-361.
24. Kohler M., Pepperell J.C., Casadei B., Craig S., Crosthwaite N., Stradling J.R., et al. CPAP and measures of cardiovascular risk in males with OSAS. Eur Respir J 2008, 32:1488-1496.
25. Mills P.J., Kennedy B.P., Loredo J.S., Dimsdale J.E., Ziegler M.G. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. JAppl Physiol (1985) 2006, 100:343-348.
26. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., Martinez I., Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006, 27:1106-1113.
27. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Hopper K., Lotsikas A., Lin H.M., et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. JClin Endocrinol Metab 2000, 85:1151-1158.
28. Testelmans D., Tamisier R., Barone-Rochette G., Baguet J.P., Roux-Lombard P., Pepin J.L., et al. Profile of circulating cytokines: impact of OSA, obesity and acute cardiovascular events. Cytokine 2013, 62:210-216.
29. Minville C., Hilleret M.N., Tamisier R., Aron-Wisnewsky J., Clement K., Trocme C., et al. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea. Chest 2014, 145:525-533.
30. Armstrong M.J., Adams L.A., Canbay A., Syn W.K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59:1174-1197.
31. Chou Y.T., Chuang L.P., Li H.Y., Fu J.Y., Lin S.W., Yang C.T., et al. Hyperlipidaemia in patients with sleep-related breathing disorders: prevalence & risk factors. Indian J Med Res 2010, 131:121-125.
32. Trzepizur W., Le Vaillant M., Meslier N., Pigeanne T., Masson P., Humeau M.P., et al. Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia. Chest 2013, 143:1584-1589.
33. Dorkova Z., Petrasova D., Molcanyiova A., Popovnakova M., Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008, 134:686-692.
34. Ip M.S., Lam K.S., Ho C., Tsang K.W., Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000, 118:580-586.
35. Michailidis V., Steiropoulos P., Nena E., Papanas N., Maltezos E., Bouros D. Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea. Open Cardiovasc Med J 2011, 5:231-238.
36. Robinson G.V., Pepperell J.C., Segal H.C., Davies R.J., Stradling J.R. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004, 59:777-782.
37. Coughlin S.R., Mawdsley L., Mugarza J.A., Wilding J.P., Calverley P.M. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007, 29:720-727.
38. West S.D., Nicoll D.J., Wallace T.M., Matthews D.R., Stradling J.R. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007, 62:969-974.
39. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423.
40. Hoyos C.M., Killick R., Yee B.J., Phillips C.L., Grunstein R.R., Liu P.Y. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study. Thorax 2012, 67:1081-1089.
41. Hoyos C.M., Sullivan D.R., Liu P.Y. Effect of CPAP on the metabolic syndrome: a randomised sham-controlled study. Thorax 2013, 68:588-589.
42. Sivam S., Phillips C.L., Trenell M.I., Yee B.J., Liu P.Y., Wong K.K., et al. Effects of 8 weeks of continuous positive airway pressure on abdominal adiposity in obstructive sleep apnoea. Eur Respir J 2012, 40:913-918.
43. Craig S.E., Kohler M., Nicoll D., Bratton D.J., Nunn A., Davies R., et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax 2012, 67:1090-1096.
44. Sharma S.K., Agrawal S., Damodaran D., Sreenivas V., Kadhiravan T., Lakshmy R., et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. NEngl J Med 2011, 365:2277-2286.
45. Sharma S.K., Agrawal S., Damodaran D., Sreenivas V., Kadhiravan T., Lakshmy R., et al. Retraction: CPAP for the metabolic syndrome in patients with obstructive sleep apnea. NEngl J Med 2011, 365:2277-2286. N Engl J Med. 2013;369:1770.
46. Punjabi N.M., Shahar E., Redline S., Gottlieb D.J., Givelber R., Resnick H.E. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004, 160:521-530.
47. Iiyori N., Alonso L.C., Li J., Sanders M.H., Garcia-Ocana A., O'Doherty R.M., et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007, 175:851-857.
48. Xu J., Long Y.S., Gozal D., Epstein P.N. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic Biol Med 2009, 46:783-790.
49. Babu A.R., Herdegen J., Fogelfeld L., Shott S., Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005, 165:447-452.
50. Yang D., Liu Z., Yang H., Luo Q. Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2013, 17:33-38.
51. Abdul-Ghani M.A., Matsuda M., Balas B., DeFronzo R.A. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007, 30:89-94.
52. Prudon B., Roddy E., Stradling J.R., West S.D. Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial. Sleep Med 2013, 14:1419-1421.
53. Kritikou I., Basta M., Vgontzas A.N., Pejovic S., Liao D., Tsaoussoglou M., et al. Sleep apnoea, sleepiness, inflammation and insulin resistance in middle-aged males and females. Eur Respir J 2014, 43:145-155.
54. Weinstock T.G., Wang X., Rueschman M., Ismail-Beigi F., Aylor J., Babineau D.C., et al. Acontrolled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea. Sleep 2012, 35:617-625B.
55. Hecht L., Mohler R., Meyer G. Effects of CPAP-respiration on markers of glucose metabolism in patients with obstructive sleep apnoea syndrome: a systematic review and meta-analysis. Ger Med Sci 2011, 9. Doc20.
56. Iftikhar I.H., Khan M.F., Das A., Magalang U.J. Meta-analysis: continuous positive airway pressure improves insulin resistance in patients with sleep apnea without diabetes. Ann Am Thorac Soc 2013, 10:115-120.
57. Comondore V.R., Cheema R., Fox J., Butt A., John Mancini G.B., Fleetham J.A., et al. The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung 2009, 187:17-22.
58. Foster G.D., Borradaile K.E., Sanders M.H., Millman R., Zammit G., Newman A.B., et al. Arandomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009, 169:1619-1626.
59. Norman D., Bardwell W.A., Arosemena F., Nelesen R., Mills P.J., Loredo J.S., et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep 2008, 31:121-126.
60. Shpirer I., Copel L., Broide E., Elizur A. Continuous positive airway pressure improves sleep apnea associated fatty liver. Lung 2010, 188:301-307.
61. Weiss J.W., Liu Y., Li X., Ji E.S. Nitric oxide and obstructive sleep apnea. Respir Physiol Neurobiol 2012, 184:192-196.
62. Trzepizur W., Martinez M.C., Priou P., Andriantsitohaina R., Gagnadoux F. Microparticles and vascular dysfunction in obstructive sleep apnoea. Eur Respir J 2014, 44:207-216.
63. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. NEngl J Med 2003, 348:593-600.
64. Schmidt-Lucke C., Rossig L., Fichtlscherer S., Vasa M., Britten M., Kamper U., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111:2981-2987.
65. Volna J., Kemlink D., Kalousova M., Vavrova J., Majerova V., Mestek O., et al. Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. Med Sci Monit 2011, 17:CR491-CR497.
66. Carpagnano G.E., Kharitonov S.A., Resta O., Foschino-Barbaro M.P., Gramiccioni E., Barnes P.J. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003, 124:1386-1392.
67. Ozturk L., Mansour B., Yuksel M., Yalcin A.S., Celikoglu F., Gokhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. Clin Chim Acta 2003, 332:83-88.
68. Svatikova A., Wolk R., Lerman L.O., Juncos L.A., Greene E.L., McConnell J.P., et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005, 26:2435-2439.
69. Barcelo A., Barbe F., de la Pena M., Vila M., Perez G., Pierola J., et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006, 27:756-760.
70. Wali S.O., Bahammam A.S., Massaeli H., Pierce G.N., Iliskovic N., Singal P.K., et al. Susceptibility of LDL to oxidative stress in obstructive sleep apnea. Sleep 1998, 21:290-296.
71. Geiser T., Buck F., Meyer B.J., Bassetti C., Haeberli A., Gugger M. Invivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002, 69:229-234.
72. Maruyama K., Morishita E., Sekiya A., Omote M., Kadono T., Asakura H., et al. Plasma levels of platelet-derived microparticles in patients with obstructive sleep apnea syndrome. JAtheroscler Thromb 2012, 19:98-104.
73. de la Pena M., Barcelo A., Barbe F., Pierola J., Pons J., Rimbau E., et al. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration 2008, 76:28-32.
74. Murri M., Garcia-Delgado R., Alcazar-Ramirez J., Fernandez-Ramos A., Alcaide J., Cardona F., et al. Effect of CPAP on oxidative stress and circulating progenitor cell levels in sleep patients with apnea-hypopnea syndrome. Respir Care 2011, 56:1830-1836.
75. Yun C.H., Jung K.H., Chu K., Kim S.H., Ji K.H., Park H.K., et al. Increased circulating endothelial microparticles and carotid atherosclerosis in obstructive sleep apnea. JClin Neurol 2010, 6:89-98.
76. Butt M., Khair O.A., Dwivedi G., Shantsila A., Shantsila E., Lip G.Y. Myocardial perfusion by myocardial contrast echocardiography and endothelial dysfunction in obstructive sleep apnea. Hypertension 2011, 58:417-424.
77. Martin K., Stanchina M., Kouttab N., Harrington E.O., Rounds S. Circulating endothelial cells and endothelial progenitor cells in obstructive sleep apnea. Lung 2008, 186:145-150.
78. Simpson P.J., Hoyos C.M., Celermajer D., Liu P.Y., Ng M.K. Effects of continuous positive airway pressure on endothelial function and circulating progenitor cells in obstructive sleep apnoea: a randomised sham-controlled study. Int J Cardiol 2013, 168:2042-2048.
79. Yokoe T., Minoguchi K., Matsuo H., Oda N., Minoguchi H., Yoshino G., et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003, 107:1129-1134.
80. Chung S., Yoon I.Y., Lee C.H., Kim J.W. The effects of nasal continuous positive airway pressure on vascular functions and serum cardiovascular risk factors in obstructive sleep apnea syndrome. Sleep Breath 2011, 15:71-76.
81. Baessler A., Nadeem R., Harvey M., Madbouly E., Younus A., Sajid H., et al. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers - a meta-analysis. JInflamm (Lond) 2013, 10:13.
82. Guo Y., Pan L., Ren D., Xie X. Impact of continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2013, 17:495-503.
83. Xie X., Pan L., Ren D., Du C., Guo Y. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis. Sleep Med 2013, 14:1139-1150.
84. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
85. Bullo M., Garcia-Lorda P., Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes. Eur J Endocrinol 2002, 146:325-331.
86. Yue H.J., Mills P.J., Ancoli-Israel S., Loredo J.S., Ziegler M.G., Dimsdale J.E. The roles of TNF-alpha and the soluble TNF receptor I on sleep architecture in OSA. Sleep Breath 2009, 13:263-269.
87. Kohler M., Ayers L., Pepperell J.C., Packwood K.L., Ferry B., Crosthwaite N., et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 2009, 64:67-73.
88. Lemoine M., Serfaty L. Chronic intermittent hypoxia: a breath of fresh air in the understanding of NAFLD pathogenesis. JHepatol 2012, 56:20-22.
89. Chin K., Nakamura T., Takahashi K., Sumi K., Ogawa Y., Masuzaki H., et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med 2003, 114:370-376.
90. Kohler M., Pepperell J.C., Davies R.J., Stradling J.R. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration 2009, 78:141-146.
91. Angulo P. Nonalcoholic fatty liver disease. NEngl J Med 2002, 346:1221-1231.
92. Poynard T., Lassailly G., Diaz E., Clement K., Caiazzo R., Tordjman J., et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One 2012, 7:e30325.
93. von Kanel R., Dimsdale J.E. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 2003, 124:1956-1967.
94. von Kanel R., Natarajan L., Ancoli-Israel S., Mills P.J., Wolfson T., Gamst A.C., et al. Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea. Sleep Med 2013, 14:58-65.
95. Hui D.S., Ko F.W., Fok J.P., Chan M.C., Li T.S., Tomlinson B., et al. The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 2004, 125:1768-1775.
96. von Kanel R., Loredo J.S., Ancoli-Israel S., Dimsdale J.E. Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 2006, 10:139-146.
97. McEwen B.J., Phillips C.L., Morel-Kopp M.C., Yee B.J., Sullivan D.R., Ward C.M., et al. Diurnal changes and levels of fibrin generation are not altered by continuous positive airway pressure (CPAP) in obstructive sleep apnoea (OSA). A randomised, placebo-controlled crossover study. Thromb Haemost 2012, 108:701-709.
98. Phillips C.L., McEwen B.J., Morel-Kopp M.C., Yee B.J., Sullivan D.R., Ward C.M., et al. Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study. Thorax 2012, 67:639-644.
99. Grimaldi D., Beccuti G., Touma C., Van Cauter E., Mokhlesi B. Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. Diabetes Care 2014, 37:355-363.
100. Chirinos J.A., Gurubhagavatula I., Teff K., Rader D.J., Wadden T.A., Townsend R., et al. CPAP, weight loss, or both for obstructive sleep apnea. NEngl J Med 2014, 370:2265-2275.